Tremfya vs Stelara
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Tremfya | US Stelara | |
|---|---|---|
| Generic name | guselkumab | ustekinumab |
| Drug class | IL-23 Inhibitor (Biologic) | IL-12/IL-23 Inhibitor (Biologic) |
| Treats | Plaque psoriasis, psoriatic arthritis | Psoriasis, Crohn's disease, ulcerative colitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Janssen | Janssen |
| Year approved | 2017 | 2009 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $140M | $130M |
| Common side effects | Respiratory infections, Headache, Injection site reactions, Joint pain | Serious infections, Headache, Fatigue, Injection site reactions |
Frequently asked questions
Is Tremfya or Stelara better?
Neither is universally "better." Tremfya (guselkumab) and Stelara (ustekinumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tremfya and Stelara?
Tremfya is a IL-23 Inhibitor (Biologic) made by Janssen, while Stelara is a IL-12/IL-23 Inhibitor (Biologic) made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tremfya has the larger estimated TV advertising budget of the two.